Non-Hodgkin Lymphoma CAR T Cells: Enhancement on Synnotch Signaling, GLUT1 expression, and PGC1a expression brings Potential Clinical Advancement in Therapy

While prior therapies for malignant solid tumors mostly focused on surgical excision and/or chemotherapy/radiotherapy, it is now feasible to combat cancers via monitoring and manipulating the immune system. Hence, the main purpose of this work is to hypothesize a potential combinational therapy with prospective enhancements to Chimeric Antigen Receptor T cells, a provision of anticipated results in vivo immune compromised Rat model with Non-Hodgkin's Lymphoma. This study, based on previously done research, it suggests the inclusion of Synnotch Receptor, which can manage T cell exhaustion and alter antigen recognition by on/off switching the receptors, particularly adjusting for CD19 and supplementary CD22, CD20, and CD30. In addition to Synnotch, this work suggests that PGC1a and GLUT 1 be upregulated to deal with the problem of poor persistence in the tumor microenvironment, monitored by western blot and flow cytometry during experiments, and in addition, with the application of GM-CSF for tackling cytokine release syndrome.